This Phase II, single-centre trial aims to evaluate the combination of pembrolizumab and lenvatinib in patients with metastatic uveal melanoma (UM). Researchers suspect that prior treatment with Tebentafusp may influence the effectiveness of anti-PD-1 therapies. To investigate this, the study will include two separate groups:
- Cohort 1: Patients who have not previously received Tebentafusp.
- Cohort 2: Patients who have been treated with Tebentafusp in the past.
Both cohorts will receive the same treatment, and the study will monitor tumour response through liver MRI and chest-abdomen-pelvis CT scans every 9 weeks until disease progression. After treatment ends, a follow-up visit will take place within 28 days, and patient survival status will be tracked after discontinuation.